Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGAV | P06756 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828538 | 0.92 | MGLL (0.51) | MGLLITGB3ITGAVMAPT | |
| SCHEMBL6828522 | 0.89 | THRB (0.45) | OPRM1OPRD1MAPTRAB9A | |
| SCHEMBL6825294 | 0.88 | TP53 (0.44) | MGLLOPRM1OPRD1MAPT | |
| SCHEMBL6828344 | 0.83 | MAPT (0.44) | OPRM1OPRD1MAPT | |
| SCHEMBL6828206 | 0.83 | MAPT (0.47) | OPRM1OPRD1MAPTRAB9A | |
| SCHEMBL6828215 | 0.83 | MAPT (0.51) | OPRM1OPRD1MAPT | |
| SCHEMBL6828202 | 0.83 | MAPT (0.46) | OPRM1OPRD1MAPT | |
| SCHEMBL6825513 | 0.82 | MAPT (0.47) | MGLLMAPT | |
| SCHEMBL6828518 | 0.82 | MAPT (0.46) | MGLLMAPTRAB9A | |
| SCHEMBL6828530 | 0.81 | RXFP1 (0.48) | MGLLMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | claimed |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | PHKG1, PHKG2, MAP3K20 | MGLL 2599/4885ENPP2 2460/4885CNR1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.